Table 3.
Univariate analysis of predictors for responder to valsartan
| Variables (criteria, %) | OR (95% CI) | P |
|---|---|---|
| Age (≥65 years, 51.2%) | 1.27 (0.74–2.16) | 0.39 |
| Sex (male, 43.7%) | 0.94 (0.55–1.61) | 0.82 |
| BMI (≥25 kg/m2, 38.3%)* | 1.22 (0.70–2.13) | 0.48 |
| SBP (≥160 mmHg, 48.1%) | 2.47 (1.42–4.31) | 0.001 |
| DBP (≥95 mmHg, 48.1%) | 4.47 (2.48–8.05) | <0.001 |
| Diabetes (19.5%) | 0.48 (0.25–0.93) | 0.03 |
| Dyslipidemia (27.4%) | 1.15 (0.61–2.16) | 0.67 |
| Urinary albumin excretion (≥30 mg/g creatinine, 44.4%) | 0.76 (0.44–1.31) | 0.32 |
| eGFR (<60 ml/min per 1.73m2, 20.8%) | 0.85 (0.42–1.71) | 0.64 |
| Urinary natrium (≥170 mEq/creatinine, 50.2%) | 1.28 (0.74–2.22) | 0.37 |
| Plasma renin activity (≥0.5 ng · ml−1 · h−1, 56.3%) | 1.08 (0.63–1.85) | 0.77 |
| ACE (>15.0 IU/l, 38.3%) | 1.22 (0.70–2.13) | 0.48 |
| Angiotensin I (≥50.0 pg/ml, 59.9%) | 1.07 (0.59–1.93) | 0.83 |
| Angiotensin II (≥5.0 pg/ml, 48.7%) | 1.63 (0.91–2.93) | 0.10 |
| Plasma aldosterone concentration (≥75.0 pg/ml, 44.6%) | 1.83 (1.06–3.18) | 0.03 |
| Atrial natriuretic peptide (≥20.0 pg/ml, 69.5%) | 0.77 (0.41–1.46) | 0.42 |
| REN C-5312T (CC, 35.1%) | 1.94 (1.08–3.49) | 0.03 |
| ACE deletion/insertion (II, 41.6%) | 0.95 (0.55–1.63) | 0.85 |
| AGT M235T (TT, 69.3%) | 1.08 (0.61–1.92) | 0.80 |
| AT1 A1166C (AA, 84.4%) | 0.84 (0.39–1.77) | 0.64 |
| AT2 C3123A (C/CC, 45.5%) | 1.53 (0.89–2.64) | 0.12 |
Crude ORs for responder to valsartan and 95% CIs were calculated using logistic regression for each dichotomous characteristic. Responders to valsartan were defined as subjects who had a decrease in DBP of ≥5 mmHg.
*BMI is the weight in kilograms divided by square of the height in meters.